Alto Neuroscience Class Action Lawsuit: Important Deadline and Details

Strategic Insights -

Alto Neuroscience, a biotech company specializing in brain health, is embroiled in a class action lawsuit regarding its initial public offering and subsequent stock sales. The lawsuit alleges that the company made false and misleading statements about its products, specifically ALTO-100, a treatment for major depressive disorder. The case is ongoing, with a lead plaintiff deadline set for September 19, 2025. Investors who purchased Alto stocks between February 2, 2024, and October 22, 2024, may be eligible for compensation.

Key Takeaways:

  • The lawsuit alleges that Alto made false and misleading statements about ALTO-100's effectiveness and clinical prospects.
  • The Class Period spans from February 2, 2024, to October 22, 2024, and investors who purchased Alto stocks during this time may be eligible for compensation.
  • A lead plaintiff is required to file a motion with the Court by September 19, 2025, to pursue the case.
  • The Rosen Law Firm, which filed the class action lawsuit, has a history of successful securities class actions and shareholder derivative litigation, recovering hundreds of millions of dollars for investors.
  • The firm has been ranked among the top 4 securities class action settlement firms since 2013 and achieved the largest ever securities class action settlement against a Chinese company at the time.

Statistics:

  • The Class Period spans 218 days.
  • Alto Neuroscience went public on February 2, 2024.
  • The lawsuit claims that investors suffered damages when the true details about ALTO-100's effectiveness entered the market.
  • The Rosen Law Firm recovered over $438 million for investors in 2019 alone.

Sources:

  • Newsfile Corp. - August 5, 2025 (exact date mentioned in the original text)
  • Laurence Rosen, Esq., and Philip Kim, Esq. (no dates added; names and titles from the original text)